These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 19147579)

  • 21. Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium.
    Edwards S; Meitz J; Eles R; Evans C; Easton D; Hopper J; Giles G; Foulkes WD; Narod S; Simard J; Badzioch M; Mahle L;
    Prostate; 2003 Dec; 57(4):270-9. PubMed ID: 14601023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single focus prostate cancer: pathological features and ERG fusion status.
    Falzarano SM; Zhou M; Hernandez AV; Klein EA; Rubin MA; Magi-Galluzzi C
    J Urol; 2011 Feb; 185(2):489-94. PubMed ID: 21167530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
    Tomlins SA; Mehra R; Rhodes DR; Smith LR; Roulston D; Helgeson BE; Cao X; Wei JT; Rubin MA; Shah RB; Chinnaiyan AM
    Cancer Res; 2006 Apr; 66(7):3396-400. PubMed ID: 16585160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization.
    Zhang S; Pavlovitz B; Tull J; Wang Y; Deng FM; Fuller C
    Diagn Mol Pathol; 2010 Sep; 19(3):151-6. PubMed ID: 20736744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
    Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
    Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci.
    Witte JS; Suarez BK; Thiel B; Lin J; Yu A; Banerjee TK; Burmester JK; Casey G; Catalona WJ
    Prostate; 2003 Dec; 57(4):298-308. PubMed ID: 14601026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
    Shah RB; Chinnaiyan AM
    Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer.
    Boormans JL; Hermans KG; Made AC; van Leenders GJ; Wildhagen MF; Collette L; Schröder FH; Trapman J; Verhagen PC
    Eur Urol; 2010 May; 57(5):830-5. PubMed ID: 19716227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci.
    Goode EL; Stanford JL; Peters MA; Janer M; Gibbs M; Kolb S; Badzioch MD; Hood L; Ostrander EA; Jarvik GP
    Clin Cancer Res; 2001 Sep; 7(9):2739-49. PubMed ID: 11555587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
    Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
    Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA
    Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions.
    Teixeira MR
    Am J Surg Pathol; 2008 Apr; 32(4):642-4; author reply 644. PubMed ID: 18317354
    [No Abstract]   [Full Text] [Related]  

  • 38. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
    Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
    Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
    Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F
    Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.